Evidence map›Paper›PMID 32032292›Full record

ArticleTransplantation2020

Inverse Association Between the Quantity of Human Peripheral Blood CXCR5+IFN-γ+CD8+ T Cells With De Novo DSA Production in the First Year After Kidney Transplant.

Jason M Zimmerer, Matthew W Basinger, Bryce A Ringwald, Mahmoud Abdel-Rasoul, Ronald P Pelletier, Amer Rajab, Ashraf El-Hinnawi, Hemant Parekh, Kenneth Washburn, Ginny L Bumgardner

Open access · greenAbstract read
In one paragraph

Article in Transplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Antibody-suppressor CXCR5American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2022
    Article
  8. The diagnostic role of PD-1Journal of clinical laboratory analysis · 2022
    Article
  9. CXCR5Frontiers in medicine · 2022
    Review
  10. CXCR5Journal of immunology (Baltimore, Md. : 1950) · 2021
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Jason M ZimmererDepartment of Surgery, Division of Transplant Surgery, Comprehensive Transplant Center, The Ohio State University, Columbus, OH.
Matthew W BasingerMedical Student Research Program, College of Medicine, The Ohio State University, Columbus, OH.
Bryce A RingwaldDepartment of Surgery, Division of Transplant Surgery, Comprehensive Transplant Center, The Ohio State University, Columbus, OH.
Mahmoud Abdel-RasoulCenter for Biostatistics, The Ohio State University, Columbus, OH.
Ronald P PelletierDepartment of Surgery, Division of Transplant Surgery, Comprehensive Transplant Center, The Ohio State University, Columbus, OH.
Amer RajabDepartment of Surgery, Division of Transplant Surgery, Comprehensive Transplant Center, The Ohio State University, Columbus, OH.
Ashraf El-HinnawiDepartment of Surgery, Division of Transplant Surgery, Comprehensive Transplant Center, The Ohio State University, Columbus, OH.
Hemant ParekhClinical Histocompatibility Laboratory, The Ohio State University, Columbus, OH.
Kenneth WashburnDepartment of Surgery, Division of Transplant Surgery, Comprehensive Transplant Center, The Ohio State University, Columbus, OH.
Ginny L BumgardnerDepartment of Surgery, Division of Transplant Surgery, Comprehensive Transplant Center, The Ohio State University, Columbus, OH.
The Ohio State University · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3M
Investigating a Novel Cellular Therapy to Prevent and Treat Acute Antibody Mediated Kidney Transplant RejectionR01AI139913 · NIAID · OHIO STATE UNIVERSITY · PI BUMGARDNER, GINNY L · 2019 to 2023
$2.7M
NCI NIH HHS P30 CA016058NIAID NIH HHS R01 AI139913
6 · The paper itself

Abstract

backgroundWe recently reported that a novel CXCR5IFN-γCD8 T-cell subset significantly inhibits posttransplant alloantibody production in a murine transplant model. These findings prompted the current study to investigate the association of human CD8 T cells with the same phenotype with the development of de novo donor-specific antibody (DSA) after kidney transplantation.

methodsIn the current studies, we prospectively and serially analyzed peripheral blood CD8 and CD4 T-cell subsets and monitored for the development of de novo DSA in kidney transplant recipients during the first-year posttransplant. We report results on 95 first-time human kidney transplant recipients with 1-year follow-up.

resultsTwenty-three recipients (24.2%) developed de novo DSA within 1-year posttransplant. Recipients who developed DSA had significantly lower quantities of peripheral CXCR5IFN-γCD8 T cells (P = 0.01) and significantly lower ratios of CXCR5IFN-γCD8 T cell to combined CD4 Th1/Th2 cell subsets (IFN-γCD4 and IL-4CD4 cells; P = 0.0001) compared to recipients who remained DSA-negative over the first-year posttransplant.

conclusionsOur data raise the possibility that human CXCR5IFN-γCD8 T cells are a homolog to murine CXCR5IFN-γCD8 T cells (termed antibody-suppressor CD8 T cells) and that the quantity of CXCR5IFN-γCD8 T cells (or the ratio of CXCR5IFN-γCD8 T cells to Th1/Th2 CD4 T cells) may identify recipients at risk for development of DSA.

Indexed as

HistocompatibilityKidney TransplantationAdultAgedBiomarkersCD4 Lymphocyte CountCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesFemaleHLA AntigensHumansInterferon-gammaIsoantibodiesMaleMiddle AgedPhenotypeBiomarkersCXCR5 protein, humanHLA AntigensIFNG protein, humanInterferon-gammaIsoantibodiesReceptors, CXCR5

Identifiers

PMID32032292
PMCPMC7415482
OpenAlexW3005374765

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.